Surrozen (NASDAQ:SRZNW – Get Free Report) is anticipated to post its results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.2880) per share and revenue of $0.4670 million for the quarter.
Surrozen Stock Performance
NASDAQ:SRZNW opened at $0.01 on Tuesday. Surrozen has a twelve month low of $0.00 and a twelve month high of $0.05. The company has a fifty day moving average of $0.01 and a 200-day moving average of $0.02.
About Surrozen
Surrozen, Inc is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on the discovery and development of novel therapeutics that harness the Wnt signaling pathway. The company employs a proprietary “surrogate agonist” platform to engineer bispecific antibodies that mimic natural Wnt ligands by concurrently engaging Frizzled receptors and LRP5/6 co-receptors. This approach is designed to promote tissue regeneration and modulate cellular pathways implicated in fibrosis and oncology.
Surrozen’s lead program is advancing in fibrotic disease, where restoring proper Wnt signaling may support the repair of damaged tissues in conditions such as idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Surrozen
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
